ClinicalTrials.gg
Not yet recruitingNCT07915219Updated Nov 12, 2026

A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

A Phase 3 interventional study of verducatib in Bronchiectasis, sponsored by Boehringer Ingelheim. Not yet recruiting at 394 sites in 41 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Updated Nov 12, 2026First sites in South Africa and Turkey (Türkiye)Newly registered+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,500
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 65 studies in Bronchiectasis with a site in United States — 21 open to participants now, 23 under way, 2 of them phase 3. Bronchiectasis · United States.

Planned enrollment
3rd of 52
1,500 · median 78
Started
2027
the only one that year
Phase 3
14 of 65
2 open now
Primary completion
2029-07
later than 18 of 21 live
Registered
65th of 65
by date
Lead sponsor
5 of 65
Boehringer Ingelheim

Among the 65 studies in Bronchiectasis with a site in United States, this one is the 3rd largest by planned enrollment of the 52 interventional ones that give a count, is the only one that started in 2027, is one of 14 in phase 3, reaches primary completion later than 18 of the 21 other live ones, and was the 65th registered.

Bronchiectasis

404 studies on the registry are indexed under Bronchiectasis; 125 are open to participants now.

Browse Bronchiectasis studies →

Open to participants now

21 of the 65 studies in Bronchiectasis with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Bronchiectasis studies recruiting now, 50 (54%) set no upper age limit and 13 (14%) stop at 75 or younger; 12 take children under 18; 26 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Bronchiectasis with a site in United States, or all of them as a file.
02

Study summary

This study is for adults and adolescents who are at least 12 years old and have bronchiectasis. People can participate if they completed a previous study with the study medicine called verducatib. The purpose of this study is to find out how well verducatib is tolerated when people with bronchiectasis take it for a long time. The study also looks at breathing problems, how often lung flare-ups happen, and how quickly lung function changes.

This is a roll-over study for participants who completed a previous study with verducatib: AIRTIVITY® (1397-0014) or CLAIRLEAF® (1397-0017). All participants receive verducatib. Participants take verducatib as tablets once a day at home. They may continue their usual treatment for bronchiectasis during the study.

Participants can stay in the study for up to 1 year and 9 months. Treatment with verducatib can continue for up to 1 year and 6 months. About 6 study visits are done at the study site and about 4 are done by phone. At all visits, the doctors check participants' health and collect information on any health problems that occur during the study. The doctors also look at lung flare-ups and measure lung function over time.

03

Conditions studied

  • Bronchiectasis

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants (adults and adolescents ≥12 years of age) who completed the treatment period in trials 1397-0014 or 1397-0017 as planned per protocol and did not discontinue trial treatment prematurely.
  2. Male or female participants. Women of (WOCBP) must be ready and able to use highly effective methods of per International Council of Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the participant information.
  3. Signed and dated written and assent, if applicable, prior to admission to the trial, in accordance with Good Clinical Practice (GCP) and local legislation.

Exclusion criteria

Exclusion criteria:

  1. Moderate or severe liver disease (defined by score B or C hepatic impairment), unless the investigator determines it is in the best interest of the participant to enrol in the trial.
  2. Estimated (eGFR) according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula (adults) and Chronic Kidney Disease Under 25 (CKiD-U25) (adolescents) \<30 mL/min at Visit 1 (or at the last safety assessment in the parent trial, if no more than 6 weeks passed since then), unless the investigator determines it is in the best interest of the participant to enrol in the trial.
  3. An absolute blood \<1000/mm\^3 (equivalent to \<1000 cells/µL or \<10\^9 cells/L) at Visit 1 (or at the last safety assessment in the parent trial, if no more than 6 weeks passed since then).
  4. Any findings in the medical examination and/or laboratory value assessed at Visit 1 (or at the last safety assessment in the parent trial, concerning the laboratory tests, if no more than 6 weeks passed since then), that in the opinion of the investigator may put the participant at risk by participating in the trial.
  5. Diagnosis of primary or secondary immunodeficiency made after end of treatment in preceding trial.
  6. Any relevant pulmonary, gastrointestinal, hepatic, renal, cardiovascular, metabolic, immunological, hormonal, or other disorder that, in the opinion of the investigator, may put the participant at risk by participating in the study.
  7. Participants who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
  8. Participants not expected to comply with the protocol requirements or not expected to complete the trial as scheduled, i.e. chronic alcohol or drug abuse or any other condition that, in the investigator's opinion, makes the participant an unreliable trial participant.

Further exclusion criteria apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,500 participants (estimated)

Study arms

  • Experimental
    Participants with bronchiectasis rolling over from parent trials

    Participants with bronchiectasis who completed parent trials AIRTIVITY® (1397-0014) or CLAIRLEAF® (1397-0017) and did not prematurely discontinue the trial drug.

    Drug: verducatib

Interventions

06

What researchers measure

Primary outcomes

  1. Occurrence of treatment-emergent adverse events (TEAEs) over the course of this trial

    Time frame: up to 78 weeks

Secondary outcomes

  1. Annualised rate of pulmonary exacerbations (number of events per person-time) up to Week 78

    Time frame: up to 78 weeks

  2. Time to first pulmonary exacerbation from first drug administration up to Week 78

    Time frame: up to 78 weeks

  3. Absolute change from baseline in post-bronchodilator forced expiratory volume in the first second (FEV1) %pred up to Week 78

    Time frame: at baseline, at week 78

  4. Absolute change from baseline in post-bronchodilator forced vital capacity (FVC) %pred up to Week 78

    Time frame: at baseline, at week 78

  5. High-resolution computed tomography (HRCT) substudy: Change from baseline (52-week HRCT from the parent trial) in total number of mucus plugs at Week 78

    Time frame: at baseline, at week 78

  6. HRCT substudy: Change from baseline (52-week HRCT from the parent trial) in volume of mucus plugs at Week 78

    Time frame: at baseline, at week 78

  7. HRCT substudy: Change from baseline (52-week HRCT from the parent trial) in bronchial wall area over bronchial outer area (Bwa/Boa) at Week 78

    Time frame: at baseline, at week 78

07

Study locations

394 sites

Showing the first 100 of 394 sites across 41 countries. Choose a country and city above to see the rest.

08

References and documents

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined on the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents - upon signing of a "Document Sharing Agreement". For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Jul 2029, 30 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2026
First posted
Nov 4, 2026
StartEst.
Jan 11, 2027
Primary completionEst.
Jul 31, 2029
CompletionEst.
Sep 10, 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
16 sites added, 5 sites removed — first sites in South Africa and Turkey (Türkiye)
Show 16 added (3 United States, 3 Spain, 2 Thailand, 2 Turkey (Türkiye), 1 Canada, 1 China, 1 Malaysia, 1 Portugal, 1 Singapore, 1 South Africa)
  • University of Alabama at Birmingham · Birmingham, United States
  • University of California San Francisco · San Francisco, United States
  • Massachusetts General Hospital · Boston, United States
  • Cardio 1 Medical Clinic · Winnipeg, Canada
  • Tongji Hospital, Tongji University · Shanghai, China
  • Institut Perubatan Respiratori · Kuala Lumpur, Malaysia
  • ULS de Santa Maria, E.P.E - Hospital de Santa Maria · Lisbon, Portugal
  • National University Hospital · Singapore, Singapore
  • Dr Ismail Abdullah · Cape Town, South Africa
  • Hospital Universitario Juan Ramón Jimenez · Huelva, Spain
  • Hospital Universitari Son Espases · Palma de Mallorca, Spain
  • Hospital Universitario Virgen del Rocio · Seville, Spain
  • King Chulalongkorn Memorial Hospital · Patumwan, Thailand
  • Srinagarind Hospital · Thailand, Thailand
  • Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi · Istanbul, Turkey (Türkiye)
  • Sureyyapasa Egitim ve Arastirma Hastanesi · Istanbul, Turkey (Türkiye)
Show 5 removed
  • Tongji Hospital Affiliated Tongji Medical College Huazhong University of S & T · Wuhan, China
  • ULS de Santa Maria, E.P.E · Lisbon, Portugal
  • Hospital Juan Ramón Jimenez · Huelva, Spain
  • Hospital Son Espases · Palma de Mallorca, Spain
  • Hospital Virgen del Rocio · Seville, Spain
Nov 12, 2026
Registered
First appeared on the registry
Nov 4, 2026
Show all 2 updates
  1. Nov 12, 2026
    16 sites added, 5 sites removed — first sites in South Africa and Turkey (Türkiye)
    Show 16 added (3 United States, 3 Spain, 2 Thailand, 2 Turkey (Türkiye), 1 Canada, 1 China, 1 Malaysia, 1 Portugal, 1 Singapore, 1 South Africa)
    • University of Alabama at Birmingham · Birmingham, United States
    • University of California San Francisco · San Francisco, United States
    • Massachusetts General Hospital · Boston, United States
    • Cardio 1 Medical Clinic · Winnipeg, Canada
    • Tongji Hospital, Tongji University · Shanghai, China
    • Institut Perubatan Respiratori · Kuala Lumpur, Malaysia
    • ULS de Santa Maria, E.P.E - Hospital de Santa Maria · Lisbon, Portugal
    • National University Hospital · Singapore, Singapore
    • Dr Ismail Abdullah · Cape Town, South Africa
    • Hospital Universitario Juan Ramón Jimenez · Huelva, Spain
    • Hospital Universitari Son Espases · Palma de Mallorca, Spain
    • Hospital Universitario Virgen del Rocio · Seville, Spain
    • King Chulalongkorn Memorial Hospital · Patumwan, Thailand
    • Srinagarind Hospital · Thailand, Thailand
    • Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi · Istanbul, Turkey (Türkiye)
    • Sureyyapasa Egitim ve Arastirma Hastanesi · Istanbul, Turkey (Türkiye)
    Show 5 removed
    • Tongji Hospital Affiliated Tongji Medical College Huazhong University of S & T · Wuhan, China
    • ULS de Santa Maria, E.P.E · Lisbon, Portugal
    • Hospital Juan Ramón Jimenez · Huelva, Spain
    • Hospital Son Espases · Palma de Mallorca, Spain
    • Hospital Virgen del Rocio · Seville, Spain
    + 1 other change: verification date
  2. Nov 4, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07915219
Responsible party
Sponsor
First posted
Nov 4, 2026
Start date
Jan 11, 2027 (estimated)
Primary completion
Jul 31, 2029 (estimated)
Completion
Sep 10, 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Boehringer Ingelheim
Contact
clintriage.rdg@boehringer-ingelheim.com
18002430127

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Verducatib

Start the discussion